References
- Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012
- Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004;22:1118-25
- Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009;23:488-96
- Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
- Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
- Genentech. Zelboraf US prescribing information. 2011. South San Francisco, CA, USA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf. Accessed October 6, 2015
- Bristol-Myers Squibb. Yervoy (ipilimumab) [package insert]. 2013. Princeton, NJ, USA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125377s055lbl.pdf. Accessed October 6, 2015
- Genentech. Zelboraf EMA summary of product characteristics. 2012. Grenzach-Wyhlen, Germany. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002409/WC500124317.pdf. Accessed October 6, 2015
- Bristol-Myers Squibb. Yervoy EMA summary of product characteristics. 2011. East Syracuse, NY. Grenzach-Wyhlen, Germany. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002213/WC500109299.pdf. Accessed October 6, 2015
- Roche. Zelboraf AU product information. 2015. Dee Why NSW, Australia http://www.guildlink.com.au/gc/ws/ro/pi.cfm?product=ropzelbo10615. Accessed May 9, 2016
- Bristol-Myers Squibb. Yervoy AU product information. 2015. Victoria, Australia. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2011-PI-02907-3. Accessed May 9, 2016
- Novartis Pharmaceuticals Corporation. Tafinlar US prescribing information. 2014. East Hanover, NJ, USA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202806s002lbl.pdf. Accessed October 6, 2015
- Novartis Pharmaceuticals Corporation. Mekinist US prescribing information. 2014. East Hanover, NJ, USA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204114s001lbl.pdf. Accessed January 10, 2014
- Novartis Pharmaceuticals Corporation. Tafinlar EMA summary of product characteristics. 2015. Camberley, Surrey, UK. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002604/WC500149671.pdf. Accessed October 12, 2015
- Novartis Pharmaceuticals Corporation. Mekinist EMA product characteristics. 2015. Camberley, Surrey, UK. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002643/WC500169657.pdf. Accessed October 12, 2015
- Novartis Pharmaceuticals Corporation. Tafinlar AU product information. 2015. Macquarie Park, NSW, Australia. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2013-PI-02126-1. Accessed May 9, 2016
- Novartis Pharmaceuticals Corporation. Mekinist AU product information. 2015. Macquarie Park, NSW, Australia. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2014-PI-01394-1. Accessed May 6, 2016
- Merck Sharp & Dohme. Keytruda US prescribing information. 2015. County Carlow, Ireland. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf. Accessed October 12, 2015
- Bristol-Myers Squibb Company. Opdivo US prescribing information. 2015. http://packageinserts.bms.com/pi/pi_opdivo.pdf. Accessed May 9, 2016
- Merck Sharp & Dohme. Keytruda EMA product information. 2015. Frederick, MD, USA. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003820/WC500190990.pdf. Accessed October 12, 2015
- Bristol-Myers Squibb. Opdivo EMA product characteristics. 2015. http://packageinserts.bms.com/pi/pi_opdivo.pdf. Princeton, NJ, USA. Accessed October 12, 2015
- Merck Sharp & Dohme. Keytruda AU product information. 2015. Macquarie Park, NSW, Australia. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2015-PI-01639-1. Accessed May 9, 2016
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34
- Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015;386:444-51
- Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015;16:908-19
- Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372:30-9
- Luengo-Fernandez R, Leal J, Gray A, et al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013;14:1165-74
- Commission of the European Communities. Communication from the commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on action against cancer: European partnership. Brussels, Belgium. 2009. http://ec.europa.eu/health/ph_information/dissemination/diseases/docs/com_2009_291.en.pdf. Accessed May 20, 2016
- Johnston K, Levy AR, Lorigan P, et al. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study). Eur J Cancer 2012;48:2175-82
- Maio M, Ascierto P, Testori A, et al. The cost of unresectable stage III or stage IV melanoma in Italy. J Exp Clin Cancer Res 2012;31:91
- Lorigan P, Marples M, Harries M, et al. Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: The MELODY study. Br J Dermatol 2014;170:87-95
- Ekwueme DU, Guy GP, Jr., Li C, et al. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. J Am Acad Dermatol 2011;65(5 Suppl 1):S133-S43
- Banz K, Bischoff H, Brunner M, et al. Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. Lung Cancer 2011;74:529-34
- Borovicka JH, Calahan C, Gandhi M, et al. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents. Arch Dermatol 2011;147:1403-9
- Mickisch G, Gore M, Escudier B, et al. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer 2010;102:80-6
- Khan KS, Kunz R, Kleijnen J, et al. Five steps to conducting a systematic review. J R Soc Med 2003;96:118-21
- Davies HTO, Crombie IK. What is a systematic review? Hayward Medical Communications, a division of Hayward Group plc. West Malling, Kent, UK. 2009. http://vivrolfe.com/ProfDoc/Assets/Davis%20What%20is%20a%20systematic%20review.pdf. Accessed May 9, 2016
- Bedikian AY, DeConti RC, Conry R, et al. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol 2011;22:787-93
- O'Day S, Pavlick A, Loquai C, et al. A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer 2011;105:346-52
- Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
- Costanza ME, Nathanson L, Costello WG, et al. Results of a randomized study comparing DTIC with TIC mustard in malignant melanoma. Cancer 1976;37:1654-9
- Carter RD, Krementz ET, Hill GJ 2nd, et al. DTIC (nsc-45388) and combination therapy for melanoma. I. studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065). Cancer Treat Rep 1976;60:601-9
- Hill GJ 2nd, Ruess R, Berris R, et al. Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU). Ann Surg 1974;180:167-74
- Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66
- Johnson RO, Metter G, Wilson W, et al. Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the central oncology group. Cancer Treat Rep 1976;60:183-7
- O'Day S, Gonzalez R, Lawson D, et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol 2009;27:5452-8
- Legha SS, Ring S, Papadopoulos N, et al. A phase II trial of taxol in metastatic melanoma. Cancer 1990;65:2478-81
- Einzig AI, Hochster H, Wiernik PH, et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991;9:59-64
- Wiernik PH, Schwartz EL, Einzig A, et al. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987;5:1232-9
- Walker L, Schalch H, King DM, et al. Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Res 2005;15:453-9
- Calabresi F, Aapro M, Becquart D, et al. Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Ann Oncol 1991;2:377-8
- Khayat D, Bizzari JP, Frenay M, et al. Interim report of phase II study of new nitrosourea S 10036 in disseminated malignant melanoma. J Natl Cancer Inst 1988;80:1407-8
- Kleeberg UR, Engel E, Israels P, et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res 1995;5:195-200
- Siegel R, Hauschild A, Kettelhack C, et al. Hepatic arterial fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol 2007;33:627-32
- Falkson CI, Falkson G, Falkson HC. Phase II trial of fotemustine in patients with metastatic malignant melanoma. Invest New Drugs 1994;12:251-4
- Egerer G, Lehnert T, Max R, et al. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients. Int J Clin Oncol 2001;6:25-8
- Schallreuter KU, Wenzel E, Brassow FW, et al. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine. Cancer Chemother Pharmacol 1991;29:85-7
- Leyvraz S, Spataro V, Bauer J, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997;15:2589-95
- Khayat D, Cour V, Bizzari JP, et al. Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II study. Am J Clin Oncol 1991;14:400-4
- Mornex F, Thomas L, Mohr P, et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 2003;13:97-103
- Mornex F, Thomas L, Mohr P, et al. Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma. Cancer Radiother 2003;7:1-8
- Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-64
- Di Giacomo AM, Danielli R, Calabro L, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 2011;60:467-77
- Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007;13:6681-8
- Borodic G, Hinkle DM, Cia Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg 2011;27:e87-8
- Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 2011;164:303-7
- Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19
- Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14
- Dalkey NC, Helmer O. An experimental application of the Delphi method to the use of experts. Manage Sci 1963;9:458-67
- Pill J. The Delphi method: substance, context, a critique and the annotated bibliography. Socioecon Planning Sci 1971;5:57-71
- Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563-70
- Patel PM, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 2011;47:1476-83
- Cui CL, Chi ZH, Yuan XQ, et al. Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study. Ai Zheng 2008;27:845-50
- Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010;116:1767-75
- Hersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 2011;29:489-98
- Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-8
- Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92
- Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:1087-95
- Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013;31:3205-11
- Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379:1893-901
- Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-65
- Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;371:1867-76
- Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-32
- Arondekar B, Curkendall S, Monberg M, et al. Economic burden associated with adverse events in patients with metastatic melanoma. J Manag Care Spec Pharm 2015;21:158-64
- Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012;380:1840-50
- Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-17
- Bray F, Ren JS, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132:1133-45
- Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012;380:1840-50
- Oncosight. Oncosight patient populations 2010-2015, plan A, appendix 1. Stanford, CA, USA. 2010
- Kassir N, Mouksassi M, Cox DS, et al. Population pharmacokinetics (PK) of trametinib (GSK1120212), a MEK inhibitor, in subjects with cancer. Clin Pharmacol Ther 2013;93(1 Suppl):S69
- Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001;14:280-90
- Lacy KE, Karagiannis SN, Nestle FO. Advances in the treatment of melanoma. Clin Med 2012;12:168-71